Citations

Mayo Clinic

Showing 10 of 108599 citations.

AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Cancer Research | September 21, 2023 | Volume: 83 | Issue: 21 | Pages: 3504-3506

10.1158/0008-5472.can-23-2803 | PMID 37732910 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
Impact of Climatic Factors on Varicella-Zoster Viral Infection
Dempsey, Sarah-Jane, Andersen, Louise K. , Coates, Sarah J. , Davis, Mark D. P. , Davis, Mark D.P.

International Journal of Dermatology and Venereology | September 21, 2023 | Volume: 8 | Issue: 1 | Pages: 61-62

10.1097/jd9.0000000000000347 Get It

AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2023 | Volume: 32 | Issue: 11 | Pages: 1482-1484

10.1158/1055-9965.epi-23-1118 | PMID 37732892 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Cancer Immunology Research | September 21, 2023 | Volume: 11 | Issue: 11 | Pages: 1446-1448

10.1158/2326-6066.cir-23-0765 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Cancer Prevention Research | September 21, 2023 | Volume: 16 | Issue: 11 | Pages: 591-594

10.1158/1940-6207.capr-23-0379 | PMID 37732897 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Molecular Cancer Research | September 21, 2023 | Volume: 21 | Issue: 11 | Pages: 1139-1141

10.1158/1541-7786.mcr-23-0750 | PMID 37732893 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Ali, Lestat R. , Lenehan, Patrick J. , Cardot‐Ruffino, Victoire , Costa, Andressa Dias , Bauer, Todd W. , Nowak, Jonathan A. , Wolpin, Brian M. , Abrams, Thomas A. , Patel, Anuj , Clancy, Thomas E. , Wang, Jiping , Mancias, Joseph D. , Stucky, Chee‐Chee , Bekaii‐Saab, Tanios , Merchant, Nipun B. , Slingluff, Craig L. , Rahma, Osama E. , Dougan, Stephanie K. , Dias Costa, Andressa , Katz, Matthew H G , Bauer, Todd W , Nowak, Jonathan A , Wolpin, Brian M , Abrams, Thomas A , Patel, Anuj , Clancy, Thomas E , Wang, Jiping , Mancias, Joseph D , Reilley, Matthew J , Stucky, Chee-Chee H , Bekaii-Saab, Tanios S , Elias, Rawad , Merchant, Nipun , Slingluff, Craig L , Rahma, Osama E , Dougan, Stephanie K , Lenehan, Patrick J , Katz, Matthew H. G. , Reilley, Matthew J. , Elias, Rawad

Clinical Cancer Research | September 21, 2023 | Volume: 30 | Issue: 3 | Pages: 542-553

10.1158/1078-0432.ccr-23-1444 | PMID 37733830 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors. Experimental Design: We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor. Results: PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to PD-1 blockade. However, these reactivated T cells have a robust signature of NF-κB signaling not seen in cases of PD-1 antibody response. Among paired samples between blood and tumor, several of the newly cycling clonotypes matched activated T-cell clonotypes observed in the tumor. Conclusions: Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti–PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474
Mycobacterium abscessus subspecies identification using the Deeplex Myc-TB targeted NGS assay
Buckwalter, Seanne P., Olson, Sara L., Epperson, L. Elaine , Hasan, Nabeeh A. , Khare, Reeti , Strong, Michael , Wengenack, Nancy L. , Wengenack, Nancy L , Fida, Madiha

Journal of Clinical Microbiology | September 21, 2023 | Volume: 61 | Issue: 10 | Pages: No page available

10.1128/jcm.00489-23 | PMID 37732763 Get It

Arterial Hyperoxemia During Cardiopulmonary Bypass Was Not Associated With Worse Postoperative Pulmonary Function: A Retrospective Cohort Study
Kelava, Marta , Milam, Adam J. , Mi, Junhui, Alfirevic, Andrej , Grady, Patrick, Unai, Shinya , Elgharably, Haytham , McCurry, Kenneth R. , Koprivanac, Marijan , Duncan, Andra E. , Milam, Adam J , Mi, Junhui, Grady, Patrick

Anesthesia & Analgesia | September 21, 2023 | Volume: 138 | Issue: 5 | Pages: 1003-1010

10.1213/ane.0000000000006627 | PMID 37733624 Get It

BACKGROUND: Arterial hyperoxemia may cause end-organ damage secondary to the increased formation of free oxygen radicals. The clinical evidence on postoperative lung toxicity from arterial hyperoxemia during cardiopulmonary bypass (CPB) is scarce, and the effect of arterial partial pressure of oxygen (Pa o 2 ) during cardiac surgery on lung injury has been underinvestigated. Thus, we aimed to examine the relationship between Pa o 2 during CPB and postoperative lung injury. Secondarily, we examined the relationship between Pa o 2 and global (lactate), and regional tissue malperfusion (acute kidney injury). We further explored the association with regional tissue malperfusion by examining markers of cardiac (troponin) and liver injury (bilirubin). METHODS: This was a retrospective cohort study including patients who underwent elective cardiac surgeries (coronary artery bypass, valve, aortic, or combined) requiring CPB between April 2015 and December 2021 at a large quaternary medical center. The primary outcome was postoperative lung function defined as the ratio of Pa o 2 to fractional inspired oxygen concentration (F io 2 ); P/F ratio 6 hours following surgery or before extubation. The association between CPB in-line sample monitor Pa o 2 and primary, secondary, and exploratory outcomes was evaluated using linear or logistic regression models adjusting for available baseline confounders. RESULTS: A total of 9141 patients met inclusion and exclusion criteria, and 8429 (92.2%) patients had complete baseline variables available and were included in the analysis. The mean age of the sample was 64 (SD = 13), and 68% were men (n = 6208). The time-weighted average (TWA) of in-line sample monitor Pa o 2 during CPB was weakly positively associated with the postoperative P/F ratio. With a 100-unit increase in Pa o 2 , the estimated increase in postoperative P/F ratio was 4.61 (95% CI, 0.71–8.50; P = .02). Our secondary analysis showed no significant association between Pa o 2 with peak lactate 6 hours post CPB (geometric mean ratio [GMR], 1.01; 98.3% CI, 0.98–1.03; P = .55), average lactate 6 hours post CPB (GMR, 1.00; 98.3% CI, 0.97–1.03; P = .93), or acute kidney injury by Kidney Disease Improving Global Outcomes (KDIGO) criteria (odds ratio, 0.91; 98.3% CI, 0.75–1.10; P = .23). CONCLUSIONS: Our investigation found no clinically significant association between Pa o 2 during CPB and postoperative lung function. Similarly, there was no association between Pa o 2 during CPB and lactate levels, postoperative renal function, or other exploratory outcomes.